Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as the care most people get for Primary Central Nervous System Lymphoma (PCNSL).

Trial Details

NCT ID
NCT05998642
Phase
PHASE2
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Methotrexate
  • Rituximab (where available)
  • Ibrutinib
Locations (sample)
  • Calgary, Alberta, Canada|51.05011,-114.08529
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Hamilton, Ontario, Canada|43.25011,-79.84963
  • Ottawa, Ontario, Canada|45.41117,-75.69812
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Patients must have histological or cytological evidence of primary central nervous system (CNS) lymphoma (PCNSL); patients with vitreo-retinal lymp…
  • Patients must be 18 years of age or older
  • Patients must be ineligible (≥65 years old or comorbidities) for high-dose chemotherapy and autologous stem cell transplantation. Patients must be …
  • Patients must have consented to the release of a tumour block from their brain tumour, if available (see Section 12.0). The centre/pathologist must…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →